JORDEN HAHN: Open Payments
NPI 1710679725 · WOODSBORO, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,459 in 45 payments from 16 companies in 2025. Trend: 2023 $316 · 2024 $621 · 2025 $1,459
Food & beverage: $1,459
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $202 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $169 |
| Dexcom, Inc. | 2 | $135 |
| Novo Nordisk Inc | 6 | $121 |
| Amgen Inc. | 1 | $103 |
| Teva Pharmaceuticals USA, Inc. | 1 | $103 |
| Lilly USA, LLC | 4 | $91 |
| ABBVIE INC. | 5 | $88 |
| Neurocrine BioSciences, Inc. | 1 | $83 |
| Sumitomo Pharma America, Inc. | 1 | $83 |
Products named: DEXCOM G7 GSS (161), REPATHA, AUSTEDO XR, AIRSUPRA, JARDIANCE, INGREZZA, MYFEMBREE, CAPLYTA.
Industry payments across MD — which companies pay providers there.
